DISCOUNT ZERTIFIKAT - ASTRAZENECA | Real-time Boerse Frankfurt Warrants 08:50:33 10/06/2024 pm IST | ||
| 112.2 EUR | +0.70% |
|
| Current month | +0.43% | ||
| 1 month | +1.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 10/24/10 | 112.2 | +0.70% |
| 07/24/07 | 111.4 | +0.19% |
| 06/24/06 | 111.2 | -0.01% |
| 05/24/05 | 111.2 | +0.01% |
| 04/24/04 | 111.2 | +0.02% |
Real-time Boerse Frankfurt Warrants
Last update June 10, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC3VYM |
| ISIN | DE000PC3VYM3 |
| Date issued | 25/01/2024 |
| Maturity | 21/06/2024 (11 Days) |
| Parity | 1 : 1 |
| Emission price | 106.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 112.2 € |
|---|---|
| Lowest since issue | 104.4 € |
| Spread | 0.1 € |
| Spread % | 0.09% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
173.1
USD
Spread / Average Target
+8.38%
- Stock Market
- Certificates
- Certificat
